Keros Therapeutics, Inc.

NASDAQ:KROS

Biotechnology

Healthcare
$12.00 +1.20%

+$0.13 today

Market cap
$235.49M
Beta
0.96
P/E (TTM)
-4.6
EPS (TTM)
-$2.29
52W Low $9.69High $22.55

Volume 0.55M

Average 0.36M

KROS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Keros Therapeutics, Inc.NASDAQ: KROS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares dips below year-ago levels

Q1 FY2026 weighted avg shares of 37.22M shares fell 8.2% year over year, behind the +1.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +13.8% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -8.2% toward the trailing-twelve-month pace of +1.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
37.22M+0.0% QoQ
Last fiscal yearDec 2025
37.22M-0.6% YoY
LTMMar 2026
38.92M+1.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.2%——
1 year-0.6%——
3-year CAGR+13.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
37.22M USD
Year-over-year change
-0.6%
4-year CAGR
+12.4%

Weighted Avg Shares vs competitors

How KROS compares with its peers on the latest reported figures

  • KROS's LTM Mar 2026 weighted avg shares of 38.92M shares is the 9th highest of the 10 companies compared; the peer median is 82.39M shares.
  • Its year-over-year change of +1.7% is the lowest of 10, against a peer median of +23.4%.
  • Over three fiscal years its annual growth of +13.8% compares with a peer median of +19.3%.
KROS Competitors Peer median
Weighted Avg Shares for KROS and competitors
Company Period LTM YoY 3-year CAGR
CTMXCytomX Therapeutics, Inc.LTM Mar 2026160.38M +90.3%+28.0%
ABSIAbsci CorporationLTM Mar 2026143.73M +23.4%+14.6%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 202691.34M +41.8%+29.6%
NAGENiagen Bioscience IncLTM Mar 202682.42M +1.7%+4.7%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.39M +23.5%+19.3%
VSTMVerastem, Inc.LTM Mar 202680.25M +101.5%+62.5%
MLTXMoonLake ImmunotherapeuticsLTM Mar 202665.6M +4.1%+30.0%
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
KROSKeros Therapeutics, Inc.LTM Mar 202638.92M +1.7%+13.8%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.08M +2.4%+1.4%
Peer median (excluding KROS) 82.39M+23.4%+19.3%

Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.1M0151K3.55M244.06M
Cost of Revenue00001.51M
Gross Profit20.1M0151K3.55M242.55M
Gross Margin100.0%—100.0%100.0%99.4%
Research & Development55.14M87.27M135.26M173.63M129.64M
Selling, General & Admin21.33M27.53M34.83M40.75M46.85M
Operating Expenses76.47M114.79M170.09M214.38M171.93M
Depreciation & Amortization378K674K815K1.23M1.51M
EBITDA(56.35M)(104M)(152.18M)(185.82M)93.41M
EBITDA Margin-280.4%—-100779.5%-5234.5%38.3%
Operating Income(56.37M)(114.79M)(169.94M)(210.83M)70.62M
Operating Margin-280.5%—-112543.7%-5939.0%28.9%
Interest Income01K000
Interest Expense4K1K000
Other Income / Expenses(360K)10.11M16.95M23.78M21.27M
Income Before Tax(56.73M)(104.68M)(152.99M)(187.05M)91.9M
Pre-Tax Margin-282.3%—-101319.2%-5269.1%37.7%
Income Tax Expense2.01M00300K4.88M
Net Income(58.74M)(104.68M)(152.99M)(187.35M)87.01M
Net Margin-292.3%—-101319.2%-5277.5%35.7%
EPS (Basic)(2.52)(4.15)(5.20)(5.00)2.34
EPS (Diluted)(2.52)(4.15)(5.20)(5.00)2.30
Weighted Avg Shares23.33M25.24M29.45M37.44M37.22M
Weighted Avg Shares (Diluted)23.33M25.24M29.45M37.44M37.86M

Keros Therapeutics, Inc.

NASDAQ:KROS

Intrinsic Alpha fair value

Locked

Current Price

$12.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.